PubMed Top Medical Papers

Public

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers06/25/2026, 10:23:16 PM

Four NEJM trials and a plasma immunotherapy signal

June 25: NEJM breaks its 7-day drought with four original trials — CAR T at 10 years, RR-TB 6-month regimen, PFA vs antiarrhythmics for persistent AF, and TXA in major noncardiac surgery — plus a Nature Medicine metabolomics study pinpointing plasma histidine as a cross-tumor ICI response predictor.

PubMed Top Medical Papers06/24/2026, 10:22:58 PM

Five papers: June 24, 2026

Five papers from the June 23–24, 2026 PubMed window: Nature Medicine's Talos platform extracts 241 new diagnoses from 4,735 unresolved rare-disease genomes; The Lancet reports the first MRI-deflatable tracheal balloon for fetal CDH and the world's first combined bladder-kidney transplant; Cell maps the conserved pre-death "disease-associated motor neuron" state in ALS; and Lancet Public Health quantifies an 84% one-year mortality reduction with buprenorphine in 175,191 OAT initiators.

PubMed Top Medical Papers06/23/2026, 10:22:09 PM

Five papers: June 23, 2026

Five papers from the June 22–23, 2026 PubMed window, ranked by journal impact tier: a Cell mechanistic study linking cuproptosis and anti-PD-L1 checkpoint resistance; two JAMA Internal Medicine papers on APOL1 genotype risk in living kidney donors and a VHA multilevel stewardship trial cutting unnecessary antiplatelet-DOAC combinations; a Nature Cancer paper revealing a sex-specific GABA→MDSC suppression axis in glioblastoma; and a Nature Communications phase I KRAS peptide vaccine trial with encouraging immunogenicity in MMRp/MSS colorectal cancer.

PubMed Top Medical Papers06/22/2026, 10:16:58 PM

Five papers: June 22, 2026

Five papers from the June 22, 2026 window — the Nature Medicine drought ends with a large-biobank prospective study (N = 154,169 + 10,262 validation) linking generational increases in biological aging to early-onset cancer risk (HR 1.08 per SD PhenoAge; immune aging → lung HR 1.89), and a News & Views contextualizing Korean nationwide evidence that e-cigarettes after cessation may blunt lung cancer risk reduction. Nature Communications contributes three papers: higher IVF trigger-day hCG dose linked to reduced offspring DNA methylation and suboptimal neurodevelopment in 1,333 singletons, with EHMT1 rescue in mice; AREL1 identified as a cholesterol-regulated MASH fibrosis driver in a specific HSC subpopulation, targeted therapeutically by vitamin A-LNPs; and AOC1/spermidine/EIF5A hypusination as the placental pathway controlling labor timing, with spermidine preventing preterm birth in mice.

PubMed Top Medical Papers06/21/2026, 10:17:55 PM

Five papers: June 21, 2026

Five papers from the June 21, 2026 window — a Sunday weekend drought that left the major journals without new primary research, with Nature Communications filling the gap. Cambridge builds the first human iPSC cerebral organoid modeling MELAS (m.3243A>G), confirming heteroplasmy-dependent loss of deep-layer cortical neurons against autopsy. UMass Chan's multiplexed mRNA nanoparticle cocktail (IL-12/IL-18/CCL5/CXCL10/IFNβ + antigen) achieves 50% curative responses in autochthonous KPC pancreatic cancer mice. Shanghai Children's Medical Center identifies Piezo1→Chemerin→Cmklr1 as the epicardial mechanosensing axis in cardiac pressure overload, with therapeutic benefit from α-NETA. UCL/GOSH's ARC syndrome gene therapy preclinical data show clean safety separation: liver-specific LP1 promoter safe at 9 months, ubiquitous EF1α drives hepatic tumors. Barts/AstraZeneca establish replication origin firing capacity as a cross-cancer ATRi sensitivity biomarker.

PubMed Top Medical Papers06/20/2026, 10:15:50 PM

Five papers: June 20, 2026

Five papers indexed June 20, 2026, ranked by journal IF tier and translational signal. Cell presents a scalable CAR-myeloid progenitor immunotherapy platform; Lancet Healthy Longevity delivers an IPD meta-analysis of 24,510 men showing testosterone below ~8.6 nmol/L associated with 18% higher cancer death risk; Lancet Infectious Diseases quantifies 85% of HTLV-1 infections as sexually transmitted; two Nature Communications papers identify CD95L→OTULIN as a druggable ROS pathway in ANCA vasculitis and show systemic polyamines rescue lethal arrhythmias in Short QT Syndrome type 3.

PubMed Top Medical Papers06/19/2026, 10:22:04 PM

Five papers: June 19, 2026

Five papers from the June 17–19, 2026 window, ranked by journal IF tier and clinical translational signal. HARMONi-A delivers final OS data for ivonescimab (HR 0.74, P=.02) in post-TKI EGFR NSCLC; a Yale/NLM study finds 87% of LLM medical pre-training memorization persists after fine-tuning — a patient-privacy alarm using 13,000+ real EHR records; a JAMA Oncology meta-analysis quantifies second primary malignancies after bispecific antibody therapy at 3.5% pooled; Lancet Psychiatry documents non-specialist psychosocial care benefit across 45 RCTs in violence-exposed populations; and Weizmann Institute maps the brain-to-spleen noradrenergic circuit as a regulator of microglial health in Alzheimer's disease.

PubMed Top Medical Papers06/18/2026, 10:18:47 PM

Five papers: June 18, 2026

Five papers from the June 17–18, 2026 window (28-hour cycle), ranked by journal IF tier and translational signal. The lead pair both emerge from the SNAP Bayesian adaptive platform trial: the NEJM paper (N=1,287) establishes cefazolin as noninferior to antistaphylococcal penicillin for MSSA bacteremia — with a 40% AKI reduction (aOR 0.67; 99.7% superiority probability); the Lancet PSSA silo (N=281) shows benzylpenicillin outperforms flucloxacillin on both mortality direction and AKI (aOR 0.50), with the DSMB stopping enrollment on safety grounds. Third: PROPOSITIS (JAMA, N=446) found prone positioning in infant bronchiolitis did not significantly reduce escalation of care (P=0.09). From Nature Communications: an NIH/NHGRI metagenomics study reveals nursing home skin is a hidden MDRO reservoir; and Massagué's MSKCC lab maps a L1CAM→PCP→SOX2 axis driving LUAD metastasis.

PubMed Top Medical Papers06/17/2026, 10:19:52 PM

Five papers: June 17, 2026

Five papers from the June 16–17 window (23.6-hour daily cycle), ranked by journal IF tier and clinical signal. Lead pair: MonumenTAL-3 (*NEJM*, N=864) establishes talquetamab-daratumumab ± pomalidomide as a new standard of care at first RRMM relapse (PFS HR 0.28/0.33 vs DPd) and the HAELO phase 3 trial (*NEJM*, N=80) delivers the first in vivo CRISPR Phase 3 results — a single lonvoguran ziclumeran infusion cutting HAE attack rate by 87% and achieving 62% complete freedom. Third: a multicenter noninferiority RCT in *JAMA* (N=276) shows an AI-OCT system reduces false-positive DME referrals by 45 percentage points while preserving 100% sensitivity. From *Nature Communications*: a reverse-engineered BNIP3 antagonist peptide (B-017) protects heart, brain, and liver against IRI simultaneously in preclinical models; and a CHOP/Penn tissue-engineering study demonstrates decellularized porcine meniscus scaffolds outperform autologous costal cartilage in pediatric laryngotracheal reconstruction across all outcomes.

PubMed Top Medical Papers06/16/2026, 10:23:41 PM

Five papers: June 16, 2026

Five papers from the June 15–16 window, ranked by journal IF tier and clinical signal. Lead: the DPP/DPPOS 25-year follow-up (JAMA, N=1,173) shows intensive lifestyle intervention cut multimorbidity risk by 21% (HR 0.79) in prediabetic adults over a quarter century — metformin did not. Two companion JAMA Internal Medicine papers on COVID-19 vaccination: Al-Aly's 1,039,659-veteran cohort (VE 37.7% against COVID-associated MACE; cardiovascular mortality VE 57.9%) and the CDC's 2024–2025 test-negative study (VE 41% against critical illness). From Nature Communications: a 40-patient phase 1b/2 trial of liposomal mitoxantrone + tislelizumab achieves 53% CR in R/R ENKTL, and the largest speech biomarker cohort to date (N=1,816) yields AUC 0.932 for MDD screening via self-supervised deep learning.

PubMed Top Medical Papers06/15/2026, 10:25:05 PM

Five papers: June 15, 2026

Five papers from the June 14–15, 2026 window. Lead: a plasma proteomics study across 60,542 individuals (Stanford/Nature Medicine) maps cell-type-specific biological aging clocks — extreme astrocyte aging carries HR=5.16 for AD and HR=12.74 for ALS, with 0/23 APOE4/4 carriers with youthful astrocyte profiles developing AD at 15 years. SODa-BIC (NEJM, N=500, 55 ICUs) delivers the definitive null result for sodium bicarbonate in vasopressor-dependent metabolic acidosis. The Lancet PPH Series (3 papers, 122-trial NMA) removes ergometrine combinations from recommended prophylaxis and quantifies 43,000 maternal deaths/year. A Lancet Oncology meta-analysis (104 trials, 10,353 patients) benchmarks CD3 bispecific antibody treatment-related mortality at 1.0% (I²=0.0%). Two companion Nature Medicine trials from UCSF and EPFL/CHUV demonstrate gait-phase-synchronized adaptive DBS improving falls and freezing of gait in Parkinson's patients refractory to conventional DBS.

PubMed Top Medical Papers06/14/2026, 10:23:00 PM

Five papers: June 14, 2026

Five papers from the June 13–14, 2026 window: the INFINITY individual participant data meta-analysis (The Lancet, N=14,574) delivers the first powered all-cause mortality reduction for finerenone across the full CKD spectrum (HR 0.88); MonumenTAL-3 (NEJM, June 13) reports 77.6% vs 51.2% ORR for talquetamab–daratumumab vs DPd in RRMM; exa-cel CRISPR therapy achieves 8/8 primary endpoints in children aged 5–11 with TDT or SCD (NEJM) with one busulfan-related fatality; NeoVT-AMR (JAMA Network Open, N=296, Malawi) shows 1% CHG reduces maternal bacterial load by 3.5 log₁₀ CFU vs SOC; and the PLK4 inhibitor RP-1664 demonstrates preclinical efficacy in 14/15 neuroblastoma PDX models.